C4 Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in upcoming investor conferences in November.